Acrivastine + Pseudoephedrine


Concise Prescribing Info
Indications/Uses
Allergic rhinitis.
Dosage/Direction for Use
Adult : PO Each cap contains acrivastine 8 mg and pseudoephedrine HCl 60 mg: ≥12 yr 1 cap 4-6 hrly. Max: 4 cap/day.
Dosage Details
Oral
Allergic rhinitis
Adult: Each cap contains acrivastine 8 mg and pseudoephedrine HCl 60 mg: ≥12 yr 1 cap 4-6 hrly. Max: 4 cap/day.
Renal Impairment
CrCl ≤48 mL/min: Contraindicated.
Hepatic Impairment
No dosage adjustment needed.
Contraindications
Hypersensitivity to triprolidine. Severe HTN or coronary artery disease; renal impairment (CrCl ≤48 mL/min). Concomitant use w/ pseudoephedrine-containing products and MAOIs w/ or w/in 14 days.
Special Precautions
Patients w/ heart disease, HTN, hyperthyroidism, diabetes, elevated intra-ocular pressure and prostatic enlargement. Elderly. Pregnancy and lactation.
Adverse Reactions
CNS depression, sleep disturbance, hallucinations, skin rashes, w/ or w/o irritation.
Overdosage
Symptoms: Restlessness, convulsions, irritability, palpitations, tremor, HTN and difficulty w/ micturition. Management: Emptying the stomach by gastric lavage, or use acid diuresis or dialysis to accelerate the elimination of pseudoephedrine.
Drug Interactions
May increase BP w/ antihypertensive agents, TCA or other sympathomimetic agents (e.g. decongestants, appetite suppressants and amfetamine-like psychostimulants). May reverse the antihypertensive effect of α- and β-adrenergic blockers, betanidine, guanethidine, bretylium, methyldopa and debrisoquine.
Potentially Fatal: Increased BP w/ pseudoephedrine-containing products and MAOIs.
Lab Interference
Pseudoephedrine may cause false-positive result w/ urine detection of amfetamine.
Action
Description: Acrivastine is a non-sedating antihistamine that is structurally related to triprolidine. It provides symptomatic relief by competitively blocking H2-receptor. Pseudoephedrine is both an α-and β-adrenergic receptor agonist. It causes vasoconstriction via direct stimulation of α-adrenergic receptors of the resp mucosa. It also directly stimulates β-adrenergic receptors causing bronchial relaxation, increased heart rate and contractility.
Pharmacokinetics:
Absorption: Both are readily absorbed from the GI tract. Time to peak plasma concentration: Acrivastine: Approx 1.3 hr; Pseudoephedrine: Approx 2 hr.
Distribution: Pseudoephedrine may cross the placenta, enter CSF and distributed into breast milk. Volume of distribution: Acrivastine: Approx 0.5-0.8 L/kg; Pseudoephedrine: 2.64-3.51 L/kg. Plasma protein binding: Acrivastine: Approx 50% (mainly to albumin).
Metabolism: Acrivastine: Minimal hepatic metabolism. Pseudoephedrine: Undergoes N-demethylation to norpseudoephedrine (active metabolite).
Excretion: Acrivastine: Via urine (84%); faeces (13%). Pseudoephedrine: Via urine (43-96% as unchanged drug; 1-6% as norpseudoephedrine).
Storage
Store between 15-25°C.
Disclaimer: This information is independently developed by MIMS based on Acrivastine + Pseudoephedrine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in